Tuesday, November 30, 2021

Latest Posts

OncoImmune: Raises $56M Series B Financing

  • OncoImmune, Inc., a Rockville, Md.-based clinical-stage biopharmaceutical company, completed a $56m Series B equity financing
  • The round co-led by HM Capital and a blue-chip investor
  • Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round
  • The company will also use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline
  • OncoImmune actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases
  • Then the company currently has two Phase III clinical programs to evaluate its lead product CD24Fc
- Advertisement -

Latest Posts

Don't Miss